MBD1 anticorps (C-Term)

N° du produit ABIN1882100

L’anticorps Lapin Polyclonal anti-MBD1 a été validé pour WB. Il convient pour détecter MBD1 dans des échantillons de Humain. Il y a 1 publication disponible.

Aperçu rapide pour MBD1 anticorps (C-Term) (ABIN1882100)

Antigène: MBD1 (Methyl-CpG Binding Domain Protein 1 (MBD1))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp MBD1 est non-conjugé

Application: Western Blotting (WB)

Clone: RB2371

Détail du produit anti-MBD1 anticorps

Épitope: AA 376-405, C-Term

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogène: This MBD1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 376-405 amino acids from the C-terminal region of human MBD1.

Isotype: Ig Fraction

Information d'application

Indications d'application: WB: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Date de péremption: 6 months

Références pour anticorps anti-MBD1 (ABIN1882100)

Auriol, Billard, Magdinier, Dante: "Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus." dans: Nucleic acids research, Vol. 33, Issue 13, pp. 4243-54, (2005) (PubMed).

Détails sur MBD1

Antigène: MBD1 (Methyl-CpG Binding Domain Protein 1 (MBD1))

Autre désignation: MBD1

Sujet: DNA methylation, or the addition of methyl groups to cytosine bases in the dinucleotide CpG, is imperative to proper development and regulates gene expression. The methylation pattern involves the enzymatic processes of methylation and demethylation. The demethylation enzyme was recently found to be a mammalian protein, which exhibits demethylase activity associated to a methyl-CpG-binding domain (MBD) (1). The enzyme is able to revert methylated cytosine bases to cytosines within the particular dinucleotide sequence mdCpdG by catalyzing the cleaving of the methyl group as methanol. MeCP2 and MBD1 (PCM1) are first found to repress transcription by binding specifically to methylated DNA (2). MBD2 and MBD4 (also known as MED1) were later found to colocalize with foci of heavily methylated satellite DNA and believed to mediate the biological functions of the methylation signal. Surprisingly, MBD3 does not bind methylated DNA both in vivo and in vitro. MBD1, MBD2, MBD3, and MBD4 are found to be expressed in somatic tissues, but the expression of MBD1 and MBD2 is reduced or absent in embryonic stem cells, which are known to be deficient in MeCP1 activity. MBD4 have homology to bacterial base excision repair DNA N-glycosylases/lyases (3). In some microsatellite unstable tumors MBD4 is mutated at an exonic polynucleotide tract (4).

Poids moléculaire: 66607

NCBI Accession: NP_001191065, NP_001191066, NP_001191067, NP_001191068, NP_001191069, NP_001191070, NP_001191071, NP_001191072, NP_001191080, NP_002375, NP_056669, NP_056670, NP_056671, NP_056723

UniProt: Q9UIS9